2026 New Horizons Forum Keynote Announced
The 2026 Drs. Henry and Frederick Sutro Memorial Lecture will be delivered by pioneering ophthalmic surgeon, prolific inventor, and visionary entrepreneur Dr. Eugene de Juan, Jr.
2026 Keynote Address: “Neuroprotection: the need, the opportunity, the path.”
Eugene de Juan, Jr., MD is the Jean Kelly Stock Distinguished Professor at University of California, San Francisco and Founder and Managing Partner at ForSight Labs, USA. A longtime member of the New Horizons Advisory Board, he received the 2016 Catalyst Award from Glaucoma Research Foundation in recognition of his outstanding leadership and commitment to advancing ophthalmology. His achievements include founding multiple ophthalmic companies, holding numerous patents, and establishing ForSight Labs as an incubator for ophthalmic ventures.
Updates on Past Presenting Companies
Rui Jing Jiang, CEO and Co-Founder of Avisi Technologies, presented at New Horizons Forum in 2021 and in February 2025 during the session Maverick Innovators of Glaucoma Devices. In April 2025, Avisi announced encouraging six‐month interim results from their multi-site VITA trial evaluating its VisiPlate® device, an ultra-thin, multichannel aqueous shunt in study subjects diagnosed with open-angle glaucoma. Data were presented by Eydie Miller-Ellis, MD, as a Top Paper at the American Glaucoma Society Annual Meeting in Washington, DC.
Patrick Mooney, Chief Executive Officer of SpyGlass Pharma, presented in February during the New Horizons session Reimagining Glaucoma Drugs and Drug Delivery. SpyGlass technology refers to a novel intraocular lens (IOL)-mounted drug delivery platform developed by SpyGlass Pharma that aims to provide sustained, long-term treatment for glaucoma and ocular hypertension, with promising results in early clinical trials. The drug-eluting IOL may help expand glaucoma treatment options.
Karl Schweitzer, CEO and co-founder of Eyetronic, presented at New Horizons in 2020 and 2022. Eyetronic therapy provides external neural stimulation to the optic nerve of patients suffering from glaucoma. The new non-invasive glaucoma treatment was offered for first time in US earlier this month at the Glaucoma Center of San Francisco, as part of a clinical trial led by Sunita Radhakrishnan, MD, the principal investigator of the study.
Alcon acquired Belkin Vision in July 2024, obtaining its Direct Selective Laser Trabeculoplasty (DSLT) technology, which is now being marketed as Voyager DSLT. Belkin had participated as a presenting company at New Horizons Forum in 2019, 2020, 2023, and 2024. In February 2025, Alcon announced the full US commercial availability of Voyager DSLT, the first and only such device. Alcon has participated in and supported Glaucoma 360 since the inaugural New Horizons Forum in 2012.
What KOL’s are saying about Glaucoma 360
“Glaucoma 360 is a key meeting for those who want to know about the absolute most exciting and latest breaking technologies about to disrupt the glaucoma space. The meeting is exciting, energizing, and inspiring.”
–Thomas V. Johnson, MD, PhD, The Johns Hopkins Wilmer Eye Institute
“New Horizons Forum is by far the best meeting I have attended to help my patients both clinically and in their daily lives with glaucoma. I am able to learn about new technologies that offer promise for vision restoration and integrate novel concepts to better meet my patients where they currently struggle with glaucoma.”
– Courtney Bovee, MD, Bovee Eye, Tampa Bay, FL
Glaucoma 360 is presented annually by Glaucoma Research Foundation (GRF) — a national non-profit organization dedicated to curing glaucoma and restoring vision through innovative research.